UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

An International External Validation Study of the 2014 European Society of Cardiology Guideline on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (Evidence from HCM)

O'Mahony, C; Jichi, F; Ommen, SR; Christiaans, I; Arbustini, E; Garcia-Pavia, P; Cecchi, F; ... Elliott, PM; + view all (2018) An International External Validation Study of the 2014 European Society of Cardiology Guideline on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (Evidence from HCM). Circulation , 137 (4) 10.1161/CIRCULATIONAHA.117.030437. Green open access

[img]
Preview
Text
CIRCULATIONAHA.117.030437.full.pdf - ["content_typename_Accepted version" not defined]

Download (1MB) | Preview

Abstract

Background -Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk of sudden cardiac death (SCD) and require prophylactic implantable cardioverter defibrillator (ICD) is challenging. In 2014, the European Society of Cardiology (ESC) proposed a new risk stratification method based on a risk prediction model (HCM Risk-SCD) which estimates the 5-year risk of SCD. The aim was to externally validate the 2014 ESC recommendations in a geographically diverse cohort of patients recruited from North America, Europe, The Middle East and Asia. Methods -This was an observational, retrospective, longitudinal cohort study. Results -The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD end-point within 5 years of follow-up [5-year incidence 2.4% (95% CI 1.9, 3.0)]. The validation study revealed a calibration slope of 1.02 (95% CI 0.93 to 1.12); C-index 0.70 (95% CI 0.68 to 0.72) and D-statistic 1.17 (95% CI 1.05 to 1.29). In a complete case analysis (n= 2147; 44 SCD end-points at 5 years) patients with a predicted 5-year risk of <4% (n=1524; 71%) had an observed 5-year SCD incidence of 1.4% (95% CI 0.8, 2.2); patients with a predicted risk of ≥6% (n=297; 14%) had an observed SCD incidence of 8.9% (95% CI 5.96, 13.1) at 5 years. For every 13 (297/23) ICD implantations in patients with an estimated 5 year SCD risk ≥6%, 1 patient can potentially be saved from SCD. Conclusions -This study confirms that the HCM Risk-SCD model provides accurate prognostic information which can be used to target ICD therapy in patients at the highest risk of SCD.

Type: Article
Title: An International External Validation Study of the 2014 European Society of Cardiology Guideline on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (Evidence from HCM)
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1161/CIRCULATIONAHA.117.030437
Publisher version: https://doi.org/10.1161/CIRCULATIONAHA.117.030437
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Hypertrophic cardiomyopathy, implanted cardioverter defibrillator, sudden cardiac death, ventricular fibrillation
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Pop Health Sciences > Institute of Cardiovascular Science > Clinical Science
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Maths and Physical Sciences > Dept of Statistical Science
URI: http://discovery.ucl.ac.uk/id/eprint/10041483
Downloads since deposit
33Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item